Advexin gets rolling?
This article was originally published in Pharmaceutical Approvals Monthly
Introgen is requesting clearance for a rolling BLA submission for Advexin, the firm announces Dec. 23. Submission would begin immediately and complete before the end of 2005. Introgen is seeking accelerated approval for the orphan head and neck cancer therapy, which also has fast track status. Two Phase III studies are underway. Introgen recently released Phase II data in a sub-population of recurrent, unresectable head and neck cancer showing tumor growth control in 41% of patients, with an objective response rate of 15%. Median survival was 13.5 months for patiens with tumor growth control and 31.4 months for patients with objective responses...
You may also be interested in...
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.